The useful question behind an announced sale price is simple: which amount is described as paid at closing or upfront, and what terms apply to the rest?
Two Canadian acquisition examples show why the labels matter. WELL disclosed a combined payment for two acquisitions within a larger package. Calian described an upfront amount for Galaxy and an additional earnout tied to future performance. Neither disclosure calculates what an individual owner takes home.
Start with the payment label
An earnout can make an additional future payment depend on agreed performance conditions. In its explanation of earnouts, MNP highlights the importance of defining the performance measure and accounting treatment.
For an owner reading an announcement, that creates a useful first task: keep the amount, its payment label and its conditions together. A maximum package and an amount described as paid at closing need separate entries. An unanswered question about timing should remain a question.
Two examples, with different limits
These are historical disclosures from 2026. The breakdown compares their stated components; it does not rank the transactions or combine their values. All amounts are in Canadian dollars.
WELL / OID and UnionMD: closed June 1, 2026; confirmed in the August 6 MD&A
Closing or upfront component: Approximately C$115 million paid at closing, combined for both acquisitions
Other disclosed consideration: Up to C$160 million total, including the closing payment, future earnouts and vendor financing
What remains unknown in the cited disclosures: Price allocation by acquisition; separate earnout and financing amounts, schedules and realized payments
Calian / Galaxy: June 2026 agreement; completion disclosed August 24
Closing or upfront component: Approximately C$24 million upfront; the financial statements described cash consideration
Other disclosed consideration: Up to C$27.5 million additional, tied to EBITDA performance over three years after closing
What remains unknown in the cited disclosures: Detailed thresholds and accounting formula, payment schedule, actual contingent payout and individual receipt date
These figures are disclosed consideration, not individual seller net proceeds. Seller-level fees, debt obligations and tax amounts have not been established here. Unknown payments remain unknown; they are not entered as zero.
WELL: keep the package and its parts together
WELL’s June 2 announcement describes the June 1 acquisitions of all of OID Group in Ontario and approximately 65% of UnionMD in Quebec. That is two acquisitions with different stakes, reported together.
Its August 6 management discussion and analysis, page 7, places the approximately C$115 million paid at closing within total consideration of up to C$160 million. The total includes future earnouts and vendor take-back financing. Adding the closing payment to the maximum would count it twice.
The passages cited here do not allocate the package price between the two acquisitions or separately quantify and schedule the earnout and financing components. The gap between the closing amount and maximum therefore cannot be labelled entirely an earnout. A combined package also cannot supply a separate price for either acquired stake.
The same MD&A identifies WELL’s expanded senior secured credit facility as the funding source for the closing payment. That answers a funding question; it does not identify another payment to add to the consideration or a seller debt to deduct.
Calian: a performance period is not a payout record
Calian’s financial statements approved on August 12 described the Galaxy transaction prospectively. Note 18, page 27, identifies approximately C$24 million in cash consideration and up to C$27.5 million in additional earnout consideration based on EBITDA performance over the three years after closing. Page 7 establishes Canadian dollars in thousands; the amounts here are expressed in millions.
Calian then announced completion on August 24, on the previously announced terms. Read the two dated documents together: the earlier filing describes the structure; the later release establishes that completion was announced.
The performance measure is identified, but the cited disclosures do not establish the detailed EBITDA thresholds or accounting formula, the earnout payment schedule or actual contingent payments. The three-year performance period does not establish three annual instalments. Nor does the completion announcement show that the maximum earnout was paid or establish an individual seller’s receipt date.
Questions to carry into your own discussion
Use these as DFC discussion prompts, not assumed terms or contractual rights in your own transaction:
Which amount is described as payable at closing or upfront, and which figure is a maximum that includes other components?
For each future component, what result or condition triggers payment?
How is a qualifying amount calculated, including the performance measure and accounting treatment?
When would that amount become due? Keep the measurement period and payment schedule separate.
What document or record would let you check the calculation, and which details still need an answer?
The output of that conversation can be a short component record: amount, label, condition, due date and supporting source. Leave an entry unresolved when the evidence does not answer it. These cases offer a way to read the disclosed structure; they do not supply a formula for your own take-home proceeds.